Toxicological and pre-clinical assessment of the anti-cancer compound Bp4eT

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/571379

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Cancer cells have a high iron requirement for DNA synthesis and many clinical trials showed Fe chelators are effective anti-cancer drugs. Their potential to act as anti-tumour agents has been confirmed by the entrance of Triapine into widespread NCI clinical trials. In this NHMRC Development Grant, we will perform toxicological studies to enable clinical trials of our most promising novel iron chelator to commence.

Funded Activity Details

Start Date: 01-01-2009

End Date: 01-01-2009

Funding Scheme: NHMRC Development Grants

Funding Amount: $198,900.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Medical biochemistry - carbohydrates

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

Cancer | Chemotherapy | Drug Development | Iron Chelators | Medicinal Chemistry | Pharmaceutical Intervention | Pharmacology | Therapeutics

Related Links